{
    "content": [
        {
            "authors": [
                {
                    "affiliation": [
                        "Department of Biological Sciences, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061",
                        "Academy of Integrated Science/Systems Biology, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061",
                        "Fralin Life Sciences Institute, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061",
                        "Carilion School of Medicine, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061"
                    ],
                    "name": "Lazar, Iulia M"
                },
                {
                    "affiliation": [
                        "Department of Biological Sciences, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061"
                    ],
                    "name": "Karcini, Arba"
                },
                {
                    "affiliation": [
                        "Academy of Integrated Science/Systems Biology, Virginia Tech, 1981 Kraft Drive, Blacksburg, VA 24061"
                    ],
                    "name": "Haueis, Joshua R. S"
                }
            ],
            "coi_statement": "The authors have declared no competing interest.",
            "content": "",
            "context": {},
            "copyright": "© 2022, Posted by Cold Spring Harbor Laboratory",
            "country": "",
            "doi": "10.1101/2022.03.18.484818",
            "entrez_date": "2022-04-15",
            "full_text_url": "https://www.biorxiv.org/content/10.1101/2022.03.18.484818.full",
            "journal": "bioRxiv",
            "journal_ISSN": "",
            "journal_abbreviation": "bioRxiv",
            "journal_issue": "",
            "journal_volume": "",
            "keywords": [
                "cell-membrane",
                "proteome",
                "cancer hallmarks"
            ],
            "language": "eng",
            "origin": "https://www.biorxiv.org/content/early/2022/04/15/2022.03.18.484818.source.xml",
            "pagination": "",
            "provider": "biorxiv",
            "provider_id": "10.1101/2022.03.18.484818",
            "provider_url": "https://www.biorxiv.org/content/10.1101/2022.03.18.484818",
            "publication_date": "2022-04-15",
            "publication_type": [
                "Preprint"
            ],
            "references": [
                "Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70",
                "Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674",
                "Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546–1558",
                "Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007; 8: 341–352",
                "McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 2014; 16: 717–727",
                "Al-Zoughbi W, Al-Zhoughbi W, Huang J, Paramasivan GS, Till H, Pichler M, et al.Tumor macroenvironment and metabolism. Semin. Oncol. 2014; 41(2): 281–295",
                "Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science 2017; 357(6348): eaal2380",
                "Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 2017; 3: 372–386",
                "Scheel C, Onder T, Karnoub A, Weinberg RA. Adaptation versus selection: the origins of metastatic behavior. Cancer Res. 2007; 67: 11476–11480",
                "Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019; 20: 69–84",
                "Paul, D. The systemic hallmarks of cancer. J Cancer Metastasis Treat. 2020; 6: 1–31",
                "Welch DR, Hurst DR. Defining the hallmarks of metastasis. Cancer Res. 2019; 79: 3011–3027",
                "Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31–46",
                "Corso S, Giordano S. Cell-autonomous and non–cell-autonomous mechanisms of HGF/MET–driven resistance to targeted therapies: from basic research to a clinical perspective. Cancer Discov. 2013; 3: 978–992",
                "Karcini A, Lazar IM. The SKBR3 cell-membrane proteome: role in aberrant cancer cell proliferation and resource for precision medicine applications. BioRxiv [Preprint]. 2021 bioRxiv 465642. Available from: 15. https://www.biorxiv.org/content/10.1101/2021.10.24.465642v1",
                "UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019; 47: D506–D515",
                "Hill DP, Smith B, McAndrews-Hill MS, Blake JA. Gene Ontology annotations: what they mean and where they come from. BMC Bioinformatics 2008; 9: S2. 17. https://doi.org/10.1186/1471-2105-9-S5-S2",
                "The Human Protein Atlas: 18. https://www.proteinatlas.org",
                "Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer. 2018; 18 (11), 696–705",
                "Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016; 7: 35478–35489",
                "Muriithi W, Macharia LW, Heming CP, Echevarria JL, Nyachieo A, Filho PN, Neto VM. ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol. Med. 2020; 17: 253–269",
                "Abcam. Studying hallmarks of cancer. 22. https://www.abcam.com/cancer/studying-hallmarks-of-cancer (2020",
                "Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014; 15: 1243–1253",
                "Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9, 703–719",
                "Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018; 46(W1): W537–W544",
                "Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009; 19: 1639–1645",
                "Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47: D607–D613",
                "Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003",
                "Lazar IM, Deng J, Ikenishi F, Lazar AC. Exploring the glycoproteomics landscape with advanced MS technologies. Electrophoresis 2015; 36(1):225–237",
                "Casas AI, Hassan AA, Larsen SJ, Gomez-Rangel V, Elbatreek M, Kleikers PWM, et al. From single drug targets to synergistic network pharmacology in ischemic stroke. PNAS 2019; 116 (14): 7129–7136",
                "Follis AV. Centrality of drug targets in protein networks. BMC Bioinformatics 2021; 22: Article 527",
                "Luo M, Jiao J, Wang R. Screening drug target combinations in disease-related molecular networks. BMC Bioinformatics 2019; 20 (Suppl. 7): Article 198",
                "Feng Y, Wang Q, Wang T. Drug Target Protein-Protein Interaction Networks: A Systematic Perspective. Biomed Res Int. 2017; Article 1289259",
                "Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS 2007; Comput Biol. 3(4): e59",
                "da Silva JCL, Coelho-Silva JL, Lima K, Vicari HP, Lazarini M, Costa-Lotufo LV, et al. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cell Oncol. 2021; 44(5): 1105–1117",
                "Bose M, Mukherjee P. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers. Vaccines 2020; 8(4):Article 659",
                "Yang H, Liu Y, Zhao MM, Guo Q, Zheng XK, Liu D, et al. Therapeutic potential of targeting membrane-spanning proteoglycan SDC4 in hepatocellular carcinoma. Cell Death Dis. 2021; 12(5):Article 492",
                "Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther. 2020; 214: Article 107590",
                "Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 2018; 124(20): 4080–4089",
                "Croce M, Ferrini, S, Pfeffer U, Gangemi R. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. Cancers 2019; 11(6):Article 846"
            ],
            "source": null,
            "title": "Mapping the Cell-Membrane Proteome to the Cancer Hallmarks",
            "type": "publication",
            "version": "1.0"
        }
    ],
    "context": {
        "biorxiv_source_create_publication_collection_document": {
            "abstract_title_flags": "match-all",
            "articles": 1,
            "cursor": 0,
            "direction": "",
            "filters": {},
            "from_date": "",
            "full_text": false,
            "hours": -1,
            "repo": "biorxiv",
            "sort": "relevance-rank",
            "to_date": ""
        }
    },
    "origin": null,
    "source": null,
    "title": "",
    "type": "collection",
    "version": "1.0"
}
